Legionnaires Disease

Back

Background

Legionnaires disease (LD) is the pneumonia caused by Legionella pneumophila. LD also refers to a more benign, self-limited, acute febrile illness known as Pontiac fever, which has been linked serologically to L pneumophila, although it presents without pneumonia. (See Pathophysiology and Etiology.)

L pneumophila is an important cause of nosocomial and community-acquired pneumonia (CAP) and must be considered a possible causative pathogen in any patient who presents with atypical pneumonia. (See Clinical Presentation and Workup.)

The Legionella bacterium was first identified in the summer of 1976 during the 58th annual convention of the American Legion, which was held at the Bellevue-Stratford Hotel in Philadelphia. Infection was presumed to be spread by contamination of the water in the hotel's air conditioning system. The presentation ranged from mild flulike symptoms to multisystem organ failure. Of the 182 people infected, 29 died.

Although Legionella was not identified until 1976, L pneumophila was subsequently found in a clinical specimen dating to 1943 and, according to retrospective analysis, may have been responsible for pre-1976 pneumonia epidemics in Philadelphia; Washington, DC; and Minnesota.

Legionnaires disease is the term that collectively describes infections caused by members of the Legionellaceae family.

Bacterial characteristics

The Legionella bacterium is a small, aerobic, waterborne, gram-negative, unencapsulated bacillus that is nonmotile, catalase-positive, and weakly oxidase-positive. It is a fastidious organism and does not grow anaerobically or on standard media. Buffered charcoal yeast extract (CYE) agar is the primary medium used for isolation of the bacterium. (See Workup.)

The Legionellaceae family consists of more than 42 species, constituting 64 serogroups. L pneumophila is the most common species, causing up to 90% of the cases of legionellosis, followed by L micdadei (otherwise known as the Pittsburgh pneumonia agent), L bozemanii, L dumoffii, and L longbeachae. Fifteen serogroups of L pneumophila have been identified, with serogroups 1, 4, and 6 being the primary causes of human disease. Serogroup 1 is thought to be responsible for 80% of the reported cases of legionellosis caused by L pneumophila.[1]

Patient education

For patient education information, see Bronchoscopy.

Pathophysiology

Legionella species are obligate or facultative intracellular parasites. Water is the major environmental reservoir for Legionella; the bacteria can infect and replicate within protozoa such as Acanthamoeba and Hartmannella, which are free-living amoebae found in natural and manufactured water systems. (Legionellae can resist low levels of chlorine used in water distribution systems.)

Within the amebic cells, Legionella species can avoid the endosomal-lysosomal pathway and can replicate within the phagosome. Surviving and growing in amebic cells allows Legionella to persist in nature. (See the image below.)



View Image

This electron micrograph depicts an amoeba, Hartmannella vermiformis (orange), as it entraps a Legionella pneumophila bacterium (green) with an extend....

Legionella species infect human macrophages and monocytes; intracellular replication of the bacterium is observed within these cells in the alveoli. The intracellular infections of protozoa and macrophages have many similarities.

Activated T cells produce lymphokines that stimulate increased antimicrobial activity of macrophages. This cell-mediated activation is key to halting the intracellular growth of legionellae. The significant role of cellular immunity explains why legionellae are observed more frequently in immunocompromised patients. Humoral immunity is thought to play a secondary role in the host response to legionellae infection.

Etiology

Legionella transmission is thought to occur via inhalation of aerosolized mist from water sources, such as the following, that have been contaminated with the bacterium[2, 3] :

Legionnaires disease may be travel associated from exposure in aircraft or hotel facilities. Person-to-person transmission, however, has not been documented.

The highest incidence of Legionnaires disease occurs during late spring and early fall, when air-conditioning systems are used more frequently.[5, 6] Nosocomial acquisition likely occurs via aspiration, respiratory therapy equipment,[3] or contaminated water. In addition, transmission has been linked to the use of humidifiers, nebulizers, and items that were rinsed with contaminated tap water.

The following features increase the likelihood of colonization and amplification of legionellae in human-made water environments:

Risk factors

The risk of infection increases with the type and intensity of the exposure, as well as the health status of the exposed individual. Numerous factors increase the risk of acquiring legionellae infections, including the following:

Epidemiology

Occurrence in the United States

LD has a reported incidence of 8000-18,000 cases per year. In certain geographic areas, community-acquired LD is more common. Although LD is reportable in all 50 states, it is estimated that only 5-10% of cases are reported. While most cases of the disease are sporadic, 10-20% of them are linked to outbreaks. LD is more common in the summer, especially in August, and is slightly more prevalent in the northern US.

Prevalence reports for Legionella have increased with time, likely due to the availability of more effective testing modalities. However, it is also possible that Legionella infections are increasing in frequency for environmental, population-based, or behavioral reasons.

LD is among the top 3-4 microbial causes of CAP, constituting approximately 1-9% of patients with CAP who require hospitalization. LD is an even more common cause of severe pneumonia in patients who require admission to an intensive care unit (ICU), ranking second, after pneumococcal pneumonia, in such cases. In addition, it has become recognized as the most common cause of atypical pneumonia in hospitalized patients.

LD cases acquired in the hospital usually occur as outbreaks and most often result from the presence of legionellae in water sources and on surfaces (eg, pipes, rubber, plastics). The organism is also found in water sediment, which may explain its ability to persist despite flushing of hospital water systems.[7, 8]

International occurrence

LD is thought to occur worldwide and to be the cause of 2-15% of all CAP cases that require hospitalization. Outbreaks have been recognized throughout North America, Africa, Australia, Europe, and South America.

Sex- and age-related demographics

Men have a greater risk of acquiring L pneumophila infection. Older age is another risk factor; the weighted mean age for patients with LD is 52.7 years, with increasing incidence until age 79 years. Mortality rates are also higher in older patients. The incidence of LD in persons younger than 35 years is less than 0.1 cases per 100,000 people.

Prognosis

Recovery is variable in LD; some patients experience rapid improvement, while others have a much more protracted course despite treatment. The mortality rate approaches 50% with nosocomial infections.

Progressive respiratory failure is the most common cause of death in patients with Legionella pneumonia. However, the mortality rate depends on the comorbid conditions of the patient, as well as on the choice and timeliness of antibiotics administration. The site of acquisition (eg, nosocomial, community-acquired) may also affect the outcome.

Complications

See the list below:

A study by van Loenhout et al that included 190 patients with LD found that a year after the disease’s onset, many patients were still suffering from 1 or more adverse health effects, particularly fatigue and reduced general quality of life.[9]

History

Legionella pneumophila causes 2 distinct disease entities. Legionnaires disease (LD) is characterized by pneumonia. Pontiac fever is a short-term, milder illness than LD and is not characterized by pneumonia, instead manifesting as fever and myalgias that resolve without treatment.

The incubation period in LD ranges from 2-10 days. Patients who develop legionellae infection and who have been hospitalized continuously for 10 or more days before the onset of illness are classified as having definite nosocomial LD. Patients with laboratory-confirmed infection that develops 2-9 days after hospitalization are classified as having possible nosocomial LD. Nosocomial LD occurs in clusters.

Symptoms of LD can occur as follows:

Physical Examination

Manifestations of LD may include the following:

A clinical point score, as shown in the table below, may be helpful in increasing the probability of correctly diagnosing LD and prompting specific/definitive LD testing.

Table 1. Legionnaires Disease: Six Clinical Predictors and Diagnostic Eliminators in Adults Admitted with Pneumonia a



View Table

See Table

Approach Considerations

While pneumonias caused by numerous pathogens share similar laboratory findings, hyponatremia (sodium < 130 mEq/L) secondary to the syndrome of inappropriate antidiuretic hormone (SIADH) is more common in Legionnaires disease (LD) than in pneumonias secondary to other pathogens; however, this is not specific for LD.

Other nonspecific laboratory findings in LD include the following:

Severe disease is defined by respiratory failure, bilateral pneumonia, rapidly worsening pulmonary infiltrates, or the presence of at least 2 of the following 3 characteristics:

Histologic Findings

Typically, legionellae histopathologic lesions are found in interstitial lining and alveoli with polymorphonuclear cells and macrophages.

Laboratory Studies

Tests in LD can include the following:

Culture of respiratory secretions

The definitive method for diagnosing Legionella is isolation of the organism in the respiratory secretions (ie, sputum, lung fluid, pleural fluid). However, Legionella species do not grow on standard microbiologic media but instead require buffered charcoal yeast extract (CYE) agar and cysteine for growth. Optimal growth occurs at 35-37°C.

Legionella is a slow-growing organism and can take 3-5 days to produce visible colonies. The organisms typically have a ground-glass appearance.

Routine sputum cultures have a sensitivity and specificity of 80% and 100%, respectively. Transtracheal aspiration of secretions or bronchoscopy specimen increases the sensitivity. Bronchoalveolar lavage (BAL) fluid provides a higher yield than bronchial wash specimens.

Blood cultures

Legionella can be isolated from blood, but it shows a much lower sensitivity.

Direct fluorescent antibody staining of sputum

Direct fluorescent antibody staining (DFA) is a rapid test that yields results in 2-4 hours, but it has a lower sensitivity and has fallen out of favor. The specificity of DFA is 96-99% using monoclonal antibody instead of polyclonal antibody.

A positive result depends on finding large numbers of organisms in the specimen; therefore, the sensitivity is increased when samples from the lower respiratory tract are used. DFA results rapidly become negative (in 4-6 d).

Serology

The most widely used tests include the immunofluorescent antibody (IFA) and enzyme-linked immunosorbent assay (ELISA) tests. A single increased antibody titer confirms LD if the IFA titer is greater than or equal to 1:256.

While LD serologic tests are the most readily available, they require a 4-fold increase in antibody titer (to 1:128 or greater), which takes 4-8 weeks. Paired measurements from both the acute and convalescent periods should be obtained, since an antibody response may not be apparent for up to 3 months. Of note, antibody levels do not increase in approximately one third of patients with LD.

Urinary antigen testing

The Legionella lipopolysaccharide antigen is detected with ELISA, radioimmunoassay (RIA), and the latex agglutination test. The Legionella lipopolysaccharide antigen becomes detectable in 80% of patients on days 1-3 of clinical illness. The urinary antigen assay can be used to detect only L pneumophila (serogroup 1).[11]

The advantages of urinary antigen testing include rapidity and simplicity. In addition, the relative ease of obtaining a urine sample compared with obtaining sputum specimens and the persistence of antigen secretion in patients who are on antibiotic therapy increase the usefulness of the urine antigen detection method.[11]

The urinary antigen test may initially be negative, but when positive it can remain positive for months after the acute episode has resolved.[11]

Amplification with PCR assay

Polymerase chain reaction (PCR) assay of urine, serum, and bronchiolar lavage fluid is very specific for the detection of legionellae, but the sensitivity is not greater than that of culture. The primary benefit of this procedure, like IFA titers, is that it can be used to detect infections caused by legionellae other than L pneumophila serogroup 1.

Imaging Studies

Radiography

Legionella infection almost always produces an abnormal chest radiographic finding, with the abnormalities typically being unilateral and occurring in the lower lobes. However, the abnormalities are variable and may be focal or diffuse; no typical radiographic presentation exists for LD.[12]

Rapidly progressive, asymmetrical infiltrates are nonetheless characteristic of the disease. Chest radiography often shows patchy alveolar infiltrates with consolidation in the lower lobe (although all lobes may be affected). Progression of the infiltrates may be seen despite antibiotic therapy. Up to 50% of patients have a pleural effusion. Cavity and abscess formation are rare in LD but can occur in immunocompromised hosts.

Improvement revealed on chest radiography can lag behind clinical improvement by 5-7 days; the radiographic abnormalities can take up to 3-4 months to resolve completely.

Noncontrast head CT scanning

Noncontrast head computed tomography (CT) scanning is indicated for patients with altered mental status. Findings should be normal in LD.

Procedures

Bronchoscopy

Bronchoscopy with or without BAL may be helpful in establishing or excluding the diagnosis if respiratory culture specimens are difficult to obtain. BAL fluid gives a higher yield than bronchial wash specimens.

Lumbar puncture

This procedure is indicated for patients with altered mental status. In uncomplicated LD, the cerebrospinal fluid (CSF) findings are generally normal.

Thoracentesis

If a pleural effusion is present, fluid can be evaluated using DFA or LD culture.

Approach Considerations

A delay in treatment significantly increases the risk of mortality in Legionnaires disease (LD). Therefore, include empiric anti-Legionella therapy in the regimen for severe community-acquired pneumonia (CAP) and in specific cases of nosocomial pneumonia.

Although Legionella pneumonia can present as a mild illness, most patients require hospitalization with parenteral antibiotics. Most healthy hosts exhibit clinical response to treatment within 3-5 days.

Prehospital and Emergency Department Care

Prehospital care

Oxygen therapy is the mainstay of prehospital therapy in LD. Intravenous (IV) access and fluid therapy may be indicated for dehydration or septic shock. Restraints may be required for patients with altered mental status. Seizure precautions may be indicated.

Differentiating LD with multiple rigors and altered mental status from a seizure disorder may be possible only through a clinical examination.

Emergency department care

Patient management includes the following:

Also see the Legionella home page from the Centers for Disease Control and Prevention (CDC), as well as the Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults.[13]

Inpatient Care

Patients with mild to moderate pneumonia are admitted to the hospital for parenteral antibiotics and supportive measures. Patients deemed to have a severe pneumonia may require admission to the intensive care unit (ICU) for closer monitoring. Quickly initiate empiric antibiotic treatment and obtain a diagnostic workup.

Close follow-up with a pulmonologist or infectious disease specialist is recommended following discharge.

Antibiotic Therapy

In milder cases, patients can be treated in an outpatient setting with oral antibiotics. For patients who are hospitalized and treated with IV antibiotics, start oral antibiotics while in the hospital and observe the patients for continued response. Continue oral antibiotics on an outpatient basis for 14-21 days, depending on the severity of the presenting illness. Patients should receive close follow-up care to ensure complete resolution of their respiratory symptoms.

Patients should complete the full course of antibiotics, whether the treatment is initiated in the outpatient setting or in the hospital.

Historically, erythromycin, one of the original macrolide antibiotics, was used for L pneumophila infection. Currently, however, other antibiotics, including doxycycline, tigecycline, azithromycin, and a respiratory quinolone, are preferred, because they are more active against LD activity and have superior pharmacokinetic properties (eg, better bioavailability, better penetration into macrophages, longer half-life).

For severe disease, a fluoroquinolone is recommended. With doxycycline or fluoroquinolones, rifampin does not need to be added in severely ill patients.

Consultations

Consultation with a pulmonologist or infectious disease specialist is strongly recommended in cases of LD. Because of the protean presentation of this disease, however, consultations with other specialists, including the following, may be required at one time or another:

Deterrence and Prevention

Prevention and control of nosocomial legionellosis

Legionellae should be sought in hospitalized patients with an increased risk for infection and subsequent death. If 1 definite case or 2 possible cases of nosocomial LD occur among in patients, initiate an investigation for a hospital source.

Legionellae transmission can also be discouraged through the routine maintenance of cooling towers and the use of only sterile water for filling and rinsing nebulization devices. Improved design and maintenance of cooling towers and plumbing systems can also help.

Disinfection

Superheating water to 70-80°C, with flushing of distal sites, may help to prevent water contamination.

Copper-silver ionization units—which produce metallic ions that disrupt the bacterial cell wall, thus resulting in lysis and cell death—are very effective at eradicating legionellae; they provide sustained protection.

Ultraviolet light kills legionellae by damaging cellular deoxyribonucleic acid (DNA). This modality is effective when disinfecting localized areas, but because it provides no sustained protection, adjunctive treatments must be used.

Hyperchlorination of water is no longer recommended, because legionellae are fairly chlorine resistant, and chlorine decomposes at the higher temperatures found in the hot water systems it is used to treat.

Following reports of LD in newborns who were infected during water births,[4] the Arizona Department of Health Services issues recommendation for minimizing the risk of Legionella contamination in tubs used during the water birthing process, such as flushing out stagnant water and sediment from hoses by running hot water through it for 3 minutes before using it to fill the tub.[14]

Medication Summary

Treat Legionnaires disease intravenously, and consider changing to oral antibiotic therapy with a 10- to 14-day course after patients begin to show signs of clinical improvement. A 21-day course is recommended in patients who are immunocompromised, who have severe underlying disease, or who develop severe Legionella pneumonia.

For immunosuppressed patients, fluoroquinolone therapy is recommended for several reasons. The fatality rate of Legionella pneumonia is high in this patient population.

Levofloxacin (Levaquin)

Clinical Context:  Levofloxacin, a fluoroquinolone, is used for pseudomonal infections and infections due to multidrug-resistant gram-negative organisms.

Azithromycin (Zithromax, Zmax)

Clinical Context:  Azithromycin is a macrolide antibiotic used to treat mild to moderate microbial infections.

Ciprofloxacin (Cipro, Cipro XR)

Clinical Context:  Ciprofloxacin is a fluoroquinolone with activity against pseudomonads, streptococci, methicillin-resistant Staphylococcus aureus (MRSA), S epidermidis, and most gram-negative organisms, but with no activity against anaerobes. It inhibits bacterial DNA synthesis and, consequently, bacterial growth.

Doxycycline (Vibramycin, Adoxa, Avidoxy, Doryx, Monodox)

Clinical Context:  Doxycycline inhibits protein synthesis and, thus, bacterial growth by binding to 30S and possibly 50S ribosomal subunits of susceptible bacteria.

Moxifloxacin (Avelox)

Clinical Context:  Moxifloxacin inhibits bacterial DNA synthesis and growth. Its activity is similar to that of ciprofloxacin and levofloxacin.

Rifampin (Rifadin)

Clinical Context:  Rifampin is the drug of choice (DOC) to use with erythromycin. It inhibits DNA-dependent RNA polymerase activity in susceptible cells by interacting with bacterial RNA polymerase (without inhibiting the mammalian enzyme).

Tigecycline (Tygacil)

Clinical Context:  A glycylcycline that inhibits protein synthesis by binding to the 30S ribosomal subunit of susceptible bacteria. It has demonstrated activity against both gram-positive and gram-negative anaerobes, as well as against gram-positive aerobic strains such as methicillin-resistant staphylococci, streptococci, and enterococci.

Erythromycin base (Ery-Tab, E.E.S., PCE)

Clinical Context:  Erythromycin inhibits ribonucleic acid (RNA) ̶ dependent protein synthesis, possibly by stimulating dissociation of peptidyl transfer RNA (tRNA) from ribosomes. This inhibits bacterial growth.

Clarithromycin (Biaxin, Biaxin XL)

Clinical Context:  Clarithromycin is a macrolide antibiotic that inhibits bacterial growth, possibly by blocking dissociation of peptidyl tRNA from ribosomes, causing RNA-dependent protein synthesis to arrest.

Class Summary

Empiric antimicrobial therapy must be comprehensive and should cover all likely pathogens in the context of the clinical setting.

What is Legionnaires disease?What is Legionella bacterium?What is the pathophysiology of Legionnaires disease?How does transmission of Legionella occur?What are factors that increase the risk of Legionnaires disease?What is the incidence of Legionnaires disease in the US?What is the global incidence of Legionnaires disease?How does the incidence of Legionnaires disease vary by sex and age?What is the prognosis of Legionnaires disease?What are the complications of Legionnaires disease?Which clinical history is characteristic of Legionnaires disease?What are the symptoms of Legionnaires disease?Which physical findings are characteristic of Legionnaires disease?What are the clinical predictors and diagnostic eliminators for Legionnaires disease?Which conditions are included in the differential diagnoses of Legionnaires disease?What is the role of lab testing in the diagnosis of Legionnaires disease?Which lab findings indicate severe cases of Legionnaires disease?Which histologic findings are characteristic of Legionnaires disease?Which lab tests are performed in the evaluation of Legionnaires disease?How is Legionnaires disease diagnosed?What is the role of direct fluorescent antibody staining of sputum in the diagnosis of Legionnaires disease?What is the role of serology in the diagnosis of Legionnaires disease?What is the role of urinary antigen testing in the diagnosis of Legionnaires disease?What is the role of polymerase chain reaction (PCR) assay in the diagnosis of Legionnaires disease?What is the role of radiography in the diagnosis of Legionnaires disease?What is the role of noncontrast head CT scanning in the diagnosis of Legionnaires disease?What is the role of bronchoscopy in the diagnosis of Legionnaires disease?What is the role of lumbar puncture in the diagnosis of Legionnaires disease?What is the role of thoracentesis in the diagnosis of Legionnaires disease?What is the initial treatment for Legionnaires disease?What is included in prehospital care of Legionnaires disease?What is included in emergency department (ED) care of Legionnaires disease?What are the indications for inpatient care of Legionnaires disease?What is the role of antibiotic therapy for the treatment of Legionnaires disease?Which specialists should be consulted for the treatment of Legionnaires disease?How is Legionnaires disease?Which medications are used in the treatment of Legionnaires disease?Which medications in the drug class Antibiotics are used in the treatment of Legionnaires Disease?

Author

Burke A Cunha, MD, Professor of Medicine, State University of New York School of Medicine at Stony Brook; Chief, Infectious Disease Division, Winthrop-University Hospital

Disclosure: Nothing to disclose.

Specialty Editors

Francisco Talavera, PharmD, PhD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Chief Editor

Michael Stuart Bronze, MD, David Ross Boyd Professor and Chairman, Department of Medicine, Stewart G Wolf Endowed Chair in Internal Medicine, Department of Medicine, University of Oklahoma Health Science Center; Master of the American College of Physicians; Fellow, Infectious Diseases Society of America; Fellow of the Royal College of Physicians, London

Disclosure: Nothing to disclose.

Additional Contributors

Frank C Smeeks, III, MD, Specialty Medical Director of Emergency Medicine, Applied Medico Legal Solutions

Disclosure: Nothing to disclose.

Acknowledgements

Joseph F John Jr, MD, FACP, FIDSA, FSHEA Clinical Professor of Medicine, Molecular Genetics and Microbiology, Medical University of South Carolina College of Medicine; Associate Chief of Staff for Education, Ralph H Johnson Veterans Affairs Medical Center

Disclosure: Nothing to disclose.

Eric M Kardon, MD, FACEP Attending Emergency Physician, Georgia Emergency Medicine Specialists; Physician, Division of Emergency Medicine, Athens Regional Medical Center

Eric M Kardon, MD, FACEP is a member of the following medical societies: American College of Emergency Physicians

Disclosure: Nothing to disclose.

Fred A Lopez, MD Associate Professor and Vice Chair, Department of Medicine, Assistant Dean for Student Affairs, Louisiana State University School of Medicine

Fred A Lopez, MD is a member of the following medical societies: Alpha Omega Alpha, American College of Physicians-American Society of Internal Medicine, Infectious Diseases Society of America, and Louisiana State Medical Society

Disclosure: Nothing to disclose.

Scott Savage, DO Associate Clinical Faculty, Department of Emergency Medicine, Wright State University, Boonshoft School of Medicine

Disclosure: Nothing to disclose.

Lynn E Sullivan, MD Assistant Professor of Medicine, Yale University School of Medicine

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

Jeter (Jay) Pritchard Taylor III, MD Compliance Officer, Attending Physician, Emergency Medicine Residency, Department of Emergency Medicine, Palmetto Health Richland, University of South Carolina School of Medicine; Medical Director, Department of Emergency Medicine, Palmetto Health Baptist

Jeter (Jay) Pritchard Taylor III, MD is a member of the following medical societies: American Academy of Emergency Medicine, American College of Emergency Physicians, American Medical Association, and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

References

  1. Kozak-Muiznieks NA, Lucas CE, Brown E, Pondo T, Taylor TH Jr, Frace M, et al. Prevalence of sequence types among clinical and environmental isolates of Legionella pneumophila serogroup 1 in the United States from 1982 to 2012. J Clin Microbiol. 2014 Jan. 52(1):201-11. [View Abstract]
  2. Nguyen TM, Ilef D, Jarraud S, Rouil L, Campese C, Che D. A community-wide outbreak of legionnaires disease linked to industrial cooling towers--how far can contaminated aerosols spread?. J Infect Dis. 2006 Jan 1. 193(1):102-11. [View Abstract]
  3. Woo AH, Goetz A, Yu VL. Transmission of Legionella by respiratory equipment and aerosol generating devices. Chest. 1992 Nov. 102(5):1586-90. [View Abstract]
  4. Granseth G, Bhattarai R, Sylvester T, Prasai S, Livar E. Notes from the Field: Two Cases of Legionnaires' Disease in Newborns After Water Births - Arizona, 2016. MMWR Morb Mortal Wkly Rep. 2017 Jun 9. 66 (22):590-591. [View Abstract]
  5. Brandsema PS, Euser SM, Karagiannis I, DEN Boer JW, VAN DER Hoek W. Summer increase of Legionnaires' disease 2010 in The Netherlands associated with weather conditions and implications for source finding. Epidemiol Infect. 2014 Jan 24. 1-12. [View Abstract]
  6. Halsby KD, Joseph CA, Lee JV, Wilkinson P. The relationship between meteorological variables and sporadic cases of Legionnaires' disease in residents of England and Wales. Epidemiol Infect. 2014 Jan 9. 1-8. [View Abstract]
  7. Cristino S, Legnani PP, Leoni E. Plan for the control of Legionella infections in long-term care facilities: Role of environmental monitoring. Int J Hyg Environ Health. 2011 Sep 16. [View Abstract]
  8. Lin YE, Stout JE, Yu VL. Controlling Legionella in hospital drinking water: an evidence-based review of disinfection methods. Infect Control Hosp Epidemiol. 2011 Feb. 32(2):166-73. [View Abstract]
  9. van Loenhout JA, van Tiel HH, van den Heuvel J, Vercoulen JH, Bor H, van der Velden K, et al. Serious long-term health consequences of Q-fever and Legionnaires' disease. J Infect. 2014 Jan 25. [View Abstract]
  10. Cunha BA. Hypophosphatemia: diagnostic significance in Legionnaires' disease. Am J Med. 2006 Jul. 119(7):e5-6. [View Abstract]
  11. Kashuba AD, Ballow CH. Legionella urinary antigen testing: potential impact on diagnosis and antibiotic therapy. Diagn Microbiol Infect Dis. 1996 Mar. 24(3):129-39. [View Abstract]
  12. Tan MJ, Tan JS, Hamor RH, File TM Jr, Breiman RF. The radiologic manifestations of Legionnaire's disease. The Ohio Community-Based Pneumonia Incidence Study Group. Chest. 2000 Feb. 117(2):398-403. [View Abstract]
  13. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007 Mar 1. 44 Suppl 2:S27-72. [View Abstract]
  14. [Guideline] Arizona Department of Health Services. Guidelines for water immersion and water birth. ADHS. Available at http://www.azdhs.gov/documents/licensing/special/midwives/training/guidelines-for-water-immersion-water-birth.pdf. November 2016; Accessed: June 9, 2017.
  15. Cunha BA. Legionnaires' disease: clinical differentiation from typical and other atypical pneumonias. Infect Dis Clin North Am. 2010 Mar. 24 (1):73-105. [View Abstract]
  16. Cunha BA, Strollo S, Schoch P. Extremely elevated erythrocyte sedimentation rates (ESRs) in Legionnaires' disease. Eur J Clin Microbiol Infect Dis. 2010 Dec. 29 (12):1567-9. [View Abstract]
  17. Cunha BA. Highly elevated serum ferritin levels as a diagnostic marker for Legionella pneumonia. Clin Infect Dis. 2008 Jun 1. 46 (11):1789-91. [View Abstract]

This electron micrograph depicts an amoeba, Hartmannella vermiformis (orange), as it entraps a Legionella pneumophila bacterium (green) with an extended pseudopod. After it is ingested, the bacterium can survive as a symbiont within what then becomes its protozoan host. The amoeba then becomes a so-called "Trojan horse," since, by harboring the pathogenic bacterium, the amoeba can afford it protection. In fact, in times of adverse environmental conditions, the amoeba can metamorphose into a cystic stage, enabling it, and its symbiotic resident, to withstand the environmental stress. Image courtesy of the Centers for Disease Control and Prevention and Dr. Barry S Fields.

This electron micrograph depicts an amoeba, Hartmannella vermiformis (orange), as it entraps a Legionella pneumophila bacterium (green) with an extended pseudopod. After it is ingested, the bacterium can survive as a symbiont within what then becomes its protozoan host. The amoeba then becomes a so-called "Trojan horse," since, by harboring the pathogenic bacterium, the amoeba can afford it protection. In fact, in times of adverse environmental conditions, the amoeba can metamorphose into a cystic stage, enabling it, and its symbiotic resident, to withstand the environmental stress. Image courtesy of the Centers for Disease Control and Prevention and Dr. Barry S Fields.

Diagnostic Predictors Diagnostic Eliminators
Clinical Predictors
  • Fever (>102°F)
Clinical Eliminators
  • Sore throat
  • Severe myalgias
Laboratory Predictors b
  • Highly elevated ESR (>90 mm/h) or CRP (>180 mg/L)
  • Highly elevated ferritin levels (>2 X normal)
  • Hypophosphatemia (on admission/early)
  • Highly elevated CPK (>2 X normal)
  • Microscopic hematuria (on admission)
Laboratory Eliminators
  • Leukopenia
  • Thrombocytopenia
  • Negative chest radiographic findings (no infiltrates)
Legionnaire disease very likely if >3 predictors presentLegionnaires disease very unlikely if < 3 predictors or >3 diagnostic eliminators present
Abbreviations: CPK = creatinine phosphokinase test; CRP = C-reactive protein; ESR = erythrosedimentation rate.



a Pulmonary symptoms: shortness of breath, cough, and so forth with fever and a new focal/segmental infiltrate on chest radiograph.



b Otherwise unexplained. If finding is due to an existing disorder, it should not be used as a clinical predictor.